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Abstract: This study described single nucleotide polymorphisms (SNPs) in hydrochlorothiazide-
associated genes and further assessed their correlation with blood pressure control among South
African adults living with hypertension. A total of 291 participants belonging to the Nguni tribes of
South Africa on treatment for hypertension were recruited. Nineteen SNPs in hydrochlorothiazide
pharmacogenes were selected and genotyped using MassArray. Uncontrolled hypertension was
defined as blood pressure ≥140/90 mmHg. The association between genotypes, alleles and blood
pressure response to treatment was determined by conducting multivariate logistic regression model
analysis. The majority of the study participants were female (73.19%), Xhosa (54.98%) and had blood
pressure ≥140/90 mmHg (68.73%). Seventeen SNPs were observed among the Xhosa tribe, and two
(rs2070744 and rs7297610) were detected among Swati and Zulu participants. Furthermore, alleles
T of rs2107614 (AOR = 6.69; 95%CI 1.42–31.55; p = 0.016) and C of rs2776546 (AOR = 3.78; 95%CI
1.04–13.74; p = 0.043) were independently associated with uncontrolled hypertension, whilst rs2070744
TC (AOR = 38.76; 95%CI 5.54–270.76; p = 0.00023), CC (AOR = 10.44; 95%CI 2.16–50.29; p = 0.003)
and allele T of rs7297610 (AOR = 1.86; 95%CI 1.09–3.14; p = 0.023) were significantly associated with
uncontrolled hypertension among Zulu and Swati participants. We confirmed the presence of SNPs
associated with hydrochlorothiazide, some of which were significantly associated with uncontrolled
hypertension in the study sample. Findings open doors for further studies on personalized therapy
for hypertension in the country.
Keywords: uncontrolled hypertension; hydrochlorothiazide; single nucleotide polymorphisms;
pharmacogenomics; South Africa
1. Introduction
Hypertension is the leading cause of death globally, accounting for 10.4 million deaths per year [1].
Furthermore, an estimated 1.13 billion people worldwide have been diagnosed with hypertension,
and most reside in low-middle income countries. In South Africa, the highest rate of hypertension
has been reported among individuals aged 50 years and above, with almost eight out of ten people
in this age group having been diagnosed with high blood pressure [2]. In addition, the Heart and
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Stroke Foundation of South Africa reported that one in three South Africans 15 years and older are
hypertensive [2]. The high burden of hypertension among South Africans is accompanied by low
control rates as well as adverse cardiovascular disease risk [2,3]. While epidemiological studies
have improved our understanding of the environmental factors associated with hypertension control,
more especially with regards to physical activity and diet, the role of genetics in this setting remains
unclear. Therefore, it is critical to explore genetic factors with regards to hypertension control in order
to establish genetic-based initiatives that could be applied in medical practice to reduce the burden of
hypertension and improve treatment outcomes among patients.
Hydrochlorothiazide (HCTZ) is a thiazide diuretic that is indicated for the treatment of
hypertension [4]. The drug has been shown to lower blood pressure by acting on the kidneys
to reduce sodium (Na+) reabsorption in the distal convoluted tubule [4,5]. Although HCTZ has been
used as a first-line drug for the treatment of hypertension for over six decades, blood pressure response
to the drug is highly variable [6,7]. As such, pharmacogenomics studies have investigated genetic
polymorphisms that could account for the inter-individual variability that is observed across individual
patients as well as diverse population groups. Single nucleotide polymorphisms (SNPs) in genes such
as protein kinase C alpha (PRKCA), lysine deficient protein kinase 1 (WNK1) beta-2 adrenergic receptor
(ADRB2) and nitric oxide synthase 3 (NOS3) have been of particular interest due to the role they play
in blood pressure control [8–10].
The PRKCA gene encodes an enzyme that plays an important role in the modulation of ion
channels [10]. In vivo studies suggest that this enzyme may be a fundamental regulator of cardiac
contractility and Calcium (Ca2+) handling in myocytes [11]. On the other hand, the WNK1 gene
encodes for a ubiquitously expressed protein that regulates vasoconstriction and blood pressure
response [12,13]. A study conducted among Caucasian hypertensive participants showed that an
intronic SNP, rs16960228, in PRKCA is an important predictor of HCTZ blood pressure response.
The study further demonstrated that rs16960228 A allele carriers had a greater blood pressure
response compared to GG carriers [14]. In addition, hypertensive patients with the CC genotype of
rs4791040 showed a greater reduction of diastolic blood pressure as compared to carriers of CT and
TT genotypes following HCTZ treatment [14]. Inversely, hypertensive carriers of the CC genotype of
rs2277869 (WNK1) showed increased ambulatory blood pressure as compared to carriers of CT and TT
genotypes [8], whereas genotypes (CC and CT) of rs2107614 of the WNK1 gene were associated with a
greater reduction in whole-day ambulatory blood pressure among patients with essential hypertension
who were treated with HCTZ [8].
The ADRB2 and NOS3 genes are central components of the renin–angiotensin system (RAS) that
controls blood pressure by regulating the volume of fluids in the body [7,15]. As such, polymorphisms
in these genes might influence blood pressure control. A study conducted in a cohort comprised
of 50% individuals of African origin showed that the AA and AG genotypes of rs2400707 (ADRB2)
were associated with an increased reduction in whole-day ambulatory blood pressure following
hydrochlorothiazide treatment [8]. On the other hand, it was shown that hypertensive carriers of the
CC genotype of rs2070744 (NOS3) who were treated with anti-hypertensive drugs including diuretics
may have an increased risk for resistance to medication as compared to patients with the CT or TT
genotype [16]. However, a direct association of the genotypes of rs2070744 (NOS3) with blood pressure
response to HCTZ is yet to be established.
The YEATS4 gene encodes the protein GAS41, which has been shown to mediate RNA transcription
and cell viability [17]. Unlike the ADRB2, PRKCA and WNK1 genes, there was no reference found in the
literature that connects the YEATS4 gene with pathways associated with hypertension or drug response.
However, carriers of rs7297610 (CC genotype) were associated with greater blood pressure responses
to HCTZ in comparison to T allele carriers. It was further demonstrated that such an association was
absent among atenolol-treated participants [18]. Therefore, these findings suggest that there could
be a potential mechanism where YEATS4 could affect blood pressure response to thiazide diuretic
medication. However, further research is needed to verify this association.
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Pharmacogenomics has progressed and matured into an efficient and effective tool for mapping
genes underlying human phenotypes associated with drug response. This tool holds the promise
of using genome-based technologies to improve health by effectively treating diseases including
hypertension [19–22]. However, pharmacogenomics is still in its infancy in the developing world,
and little is known about the influence of genetic factors on blood pressure response to hypertensive
treatment among Africans. In this study, we described single nucleotide polymorphisms (SNPs)
in hydrochlorothiazide-associated genes and further assessed their correlation with blood pressure
control among South African adults living with hypertension.
2. Materials and Methods
2.1. Ethical Approval
The Senate Research Committee of the University of the Western Cape approved the study protocol
(Ethics approval number: BM/16/5/19). Permission to implement the study was granted by the clinical
governance of the respective hospitals in the Eastern Cape and Mpumalanga Provinces. Participants
were issued with a research information sheet detailing the study, and it was made available in three
indigenous languages (SiSwati, IsiXhosa and IsiZulu). Each participant indicated their voluntary
participation by signing a consent form. The rights to privacy and confidentiality of the medical
information of each participant were honored during and after the study.
2.2. Patient Selection
A total of 291 Nguni (Xhosa, Swati and Zulu) patients attending chronic care for hypertension
were recruited consecutively between January 2019 and June 2019 from Cecilia Makiwane Hospital
(East London, Eastern Cape), Piet Retief Hospital, Thandukukhanya Community Health Center and
Mkhondo Town Clinic (Mkhondo, Mpumalanga). Participants were eligible for participation if they
were 18 years or older and were on continuous treatment for hypertension for at least a year prior to
the study. Individuals who were bedridden, pregnant and unable to give consent were excluded from
the study.
2.3. Data Collection
A trained research nurse measured the blood pressure (BP) of each participant by using a validated
automated digital BP monitor (Macrolife BP A 100 Plus model) according to standard protocols.
Thereafter, BP was recorded in triplicate, and the average was used to categorize participants into two
groups: controlled (blood pressure < 140/90 mmHg) and uncontrolled (blood pressure ≥ 140/90 mmHg).
DNA samples were collected in the form of buccal swabs and stored at−20 ◦C until they were processed.
The age, ethnicity, smoking status and salt intake were self-reported by each participant and
documented in a proforma designed for this study. The number and type of anti-hypertensive drugs
prescribed for each participant were retrieved from their clinical records.
2.4. DNA Isolation
Genomic DNA was extracted from buccal swab samples using a standard salt-lysis procedure.
Briefly, DNA samples were incubated in lysis buffer at 62 ◦C overnight. Thereafter, DNA was
precipitated with NaCl followed by the addition of 75% ice-cold ethanol and incubated at −20 ◦C
overnight. Precipitated DNA was purified using 70% ethanol and re-suspended in nuclease-free water.
Samples were stored in 2 mL Eppendorf tubes at −20 ◦C until further use. DNA was quantified using a
NanoDrop™ 2000/2000c spectrophotometer (Thermo Scientific™, Waltham, MA, USA) and Gel Doc™
EZ Gel Documentation System (BIO-RAD, Irvine, CA, USA).
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2.5. Genotyping
Two multiplex MassARRAY systems (Agena BioscienceTM) were designed and optimized by
Inqaba Biotechnical Industries (Pretoria, South Africa) in January 2017. Each multiplex was used to
genotype selected SNPs, using an assay that is based on a locus-specific PCR reaction. This reaction
is followed by a single base extension using the mass-modified dideoxynucleotide terminators of
an oligonucleotide primer, which anneals upstream of the site of mutation. Matrix-Assisted Laser
Desorption/Ionization–time-of-flight (MALDI-TOF) mass spectrometry was used to identify the SNP
of interest.
2.6. Statistical Analysis
Statistical analyses were performed using International Business Machines (IBM) Statistical
Package for Social Science (SPSS) Version 25 for Windows (IBM Corps, Armonk, NY, USA). The general
characteristics of the participants were expressed as frequency (percentages). The associations between
alleles, genotypes and blood pressure response to hydrochlorothiazide were assessed by multivariate
logistic regression model analysis (unadjusted and adjusted odds ratios) and their 95% confidence
intervals (95%CI). The final model of the adjusted logistic regression analysis for the Xhosa population
included rs11189015, rs1458038, rs16960228, rs17010902, rs2106809, rs2107614, rs2269879, rs2277869,
rs2400707, rs2776546, rs292449, rs4149601, rs4551053, rs4791040 and rs5051. For the Swati and Zulu
population, the final adjusted regression model analysis included rs6083538, rs2070744 and rs7297610.
Results for the unadjusted logistic regression model analysis were expressed as unadjusted odds ratios
(ORs) and adjusted odds ratios (AORs) for the adjusted logistic regression model analysis. A p-value
less than 0.05 was considered statistically significant. Bonferroni corrected p-values were set at <0.0029
for the Xhosa population and <0.025 for the Swati and Zulu population. Minor allele frequency
(MAF) and Hardy–Weinberg equilibrium (HWE) tests were calculated using Genetic Analysis in Excel
(GenAIEx) Version 6.5.
2.7. Selection of Pharmacogenomics Biomarkers
Nineteen SNPs previously associated with hypertension or hydrochlorothiazide efficacy were
selected using Pharmacogenomics Knowledge Base Ensembl [23] as well as an extensive survey of
recent literature. Selected SNPs were in genes that are indirectly or directly involved in the pathways
associated with the blood-pressure-lowering effect of hydrochlorothiazide on hypertension exhibiting
a PharmGKB evidence rating of at least 3.
3. Results
3.1. General Characteristics of the Study
A total of 291 individuals with hypertension participated in this study, of whom 73.19% (n = 213)
were female and 26.04% (n = 78) were male. The mean age (SD) of the participants was 60.45 ± 11.90
years. The cohort was composed of individuals belonging to the Xhosa (n = 160), Zulu (n = 112) and
Swati (n = 19) tribes of South Africa. The majority of the participants were non-smokers (67.35%),
consumed low-moderate salt (81.44%) and had blood pressure ≥140/90 mmHg (68.73%) (Table 1).
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Table 1. General characteristics of the study cohort. HCTZ: hydrochlorothiazide.
Variables All Participants (n; %) Males (n; %) Females (n; %)
All 291(100) 78(26.04) 213(73.19)
Age (Years)
18–25 01(0.34) 01(1.28) 0(0.00)
26–35 08(2.75) 02(2.56) 06(2.82)
36–45 19(6.52) 07(8.97) 12(6.63)
46–55 52(17.87) 14(17.95) 38(17.84)
56–65 120(41.24) 25(32.05) 95(44.60)
≥66 91(31.27) 29(37.18) 62(29.11)
Ethnicity
Zulu 112(38.49) 19(24.36) 93(43.66)
Swati 19(6.53) 03(3.85) 16(7.51)
Xhosa 160(54.98) 56(71.79) 104(48.83)
Smoking status
Never smoked 196(67.35) 30(38.46) 166(77.93)
Ever smoked 95(32.65) 48(61.54) 47(22.07)
Salt intake
Low-moderate 237(81.44) 58(74.36) 179(84.04)
Increased 54(18.56) 20(25.64) 34(15.96)
Blood pressure
<140/90 mmHg 91(31.26) 16(20.51) 75(35.21)
≥140/90 mmHg 200(68.73) 62(79.49) 138(64.79)
Drug regime
HCTZ alone 63(21.65) 20(25.64) 43(20.19)
HCTZ + 1 drug 127(43.64) 26(33.33) 101(47.42)
HCTZ+ 2 drugs 98(33.68) 30(38.46) 68(31.92)
HCTZ + 3 drugs 03(1.03) 02(2.56) 01(0.47)
Anti-hypertensive drugs used in different combinations: Amlodipine, Enalapril and Atenolol.
3.2. Expression Patterns of Single Nucleotide Polymorphisms
Nineteen SNPs were selected and their expression patterns were assessed across three populations
(Swati, Xhosa and Zulu). Seventeen out of nineteen SNPs were exclusively detected among the Xhosa
tribe (n = 160), the remaining two (rs2070744 and rs7297610) were detected among Swati and Zulu
participants. The majority of the seventeen SNPs detected among the Xhosa tribe demonstrated an
expression frequency above 90%, with variants rs4791040 and rs5051 showing an expression frequency
of 73.10% (n = 117) and 68.75% (n = 110), respectively. Variant rs2070744 and rs5051 showed a
100% expression efficiency among Swati (n = 19) and Zulu (n = 112) participants, of whom 51.17%
(n = 109) were female, and 44.44% (n = 40) were aged 60 years and above (Table 2). The minor allele
frequency (MAF) observed in all three populations was compared to the Luhya people of Kenya,
the Yoruba of Nigeria, Mexican from California (USA), British of Great Britain and Punjabi of India.
Variants rs11189015 (33.5%), rs17010902 (59.5%), rs2106809 (88.5%) and rs2277869 (20.5%) detected
among the Xhosa tribe showed a higher MAF in comparison to the selected reference populations
listed on Ensembl (23). However, the MAFs of rs2269879 (32.2%), rs2400707 (37.26%) and rs1458038
(20.3%) were lower than those observed in the selected world populations. The MAFs of the remaining
SNPs are shown in Table 3. Variant rs7297610 (52.4%) detected among the Swati and Zulu tribe showed
a higher MAF when compared to the selected world populations. The MAF observed in variant
rs2070744 (14.7%) was lower than the MAF observed among British, Mexican and Punjabi populations
(Table 3). None of the SNPs in this cohort deviated from the Hardy–Weinberg equilibrium.
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Table 2. Distribution patterns of selected single nucleotide polymorphisms (SNPs).
dbSNP Gene
Ethnic Groups Gender Age
Zulu (n; %) Swati (n; %) Xhosa (n; %) Male (n; %) Female (n; %) <55 Years 55–65 Years >65 Years
All 112(38.48) 19(6.52) 160(54.98) 78(26.80) 213(73.19) 80(27.49) 121(41.58) 90(30.93)
rs11189015 SLIT1
Yes - - 155(96.88) 54(69.23) 101(47.42) 43(53.75) 62(51.24) 50(55.56)
No 112(100) 19(100) 05(3.10) 24(30.77) 112(52.58) 37(46.25) 59(48.76) 40(44.44)
rs1458038 FGF5
Yes - - 156(97.50) 55(70.51) 101(47.42) 45(56.25) 62(51.24) 49(54.44)
No 112(100) 19(100) 04(2.50) 23(29.49) 112(52.58) 35(43.75) 59(48.76) 41(45.56)
rs16960228 PRKCA
Yes - - 158(98.75) 56(71.79) 102(47.89) 47(58.75) 63(52.07) 48(53.33)
No 112(100) 19(100) 02(1.25) 22(28.21) 111(52.11) 33(41.25) 58(47.93) 42(46.67)
rs17010902 APOA5
Yes - - 152(95.00) 54(69.23) 98(46.01) 44(55.00) 61(50.41) 47(52.22)
No 112(100) 19(100) 08(5.00) 24(30.77) 115(53.99) 36(45.00) 60(49.59) 43(47.78)
rs2106809 ACE2
Yes - - 157(98.10) 54(69.23) 103(48.36) 45(56.25) 62(51.24) 50(55.56)
No 112(100) 19(100) 03(1.90) 24(30.77) 110(51.64) 35(43.75) 59(48.76) 40(44.44)
rs2107614 WNK1
Yes - - 155(96.90) 55(70.51) 100(46.95) 47(58.75) 62(51.24) 46(51.11)
No 112(100) 19(100) 05(3.10) 23(29.49) 113(53.05) 33(41.25) 59(48.76) 44(48.89)
rs2269879 DOT1L
Yes - - 156(97.50) 54(69.23) 102(47.89) 44(55.00) 63(52.07) 49(54.44)
No 112(100) 19(100) 04(2.50) 24(30.77) 111(52.11) 36(45.00) 58(47.93) 41(45.56)
rs2277869 WNK1
Yes - - 156(97.50) 55(70.51) 101(47.42) 46(57.50) 61(50.41) 49(54.44)
No 112(100) 19(100) 04(2.50) 23(29.49) 112(52.58) 34(42.50) 60(49.59) 41(45.56)
rs2400707 ADRB2
Yes - - 157(98.10) 56(71.79) 101(47.42) 45(56.25) 63(52.07) 49(54.44)
No 112(100) 19(100) 03(1.90) 22(28.21) 112(52.58) 35(43.75) 58(47.93) 41(45.56)
rs2776546 CSMD1
Yes - - 158(98.75) 56(71.79) 102(47.89) 47(58.75) 63(52.07) 48(53.33)
No 112(100) 19(100) 02(1.25) 22(28.21) 111(52.11) 33(41.25) 58(47.93) 42(46.67)
rs292449 NEDD4L
Yes - - 156(97.50) 55(70.51) 101(47.42) 45(56.25) 63(2.07) 48(53.33)
No 112(100) 19(100) 04(2.50) 23(29.49) 112(52.58) 35(43.75) 58(47.93) 42(46.67)
rs3184504 SH2B3
Yes - - 159(99.40) 56(71.79) 103(48.36) 47(58.75) 63(52.07) 49(54.44)
No 112(100) 19(100) 01(0.60) 22(28.21) 110(51.64) 33(41.25) 58(47.93) 41(45.56)
rs4149601 NEDD4L
Yes - - 159(99.40) 56(71.79) 103(48.36) 47(58.75) 63(52.07) 49(54.44)
No 112(100) 19(100) 01(0.60) 22(28.21) 110(51.64) 33(41.25) 58(47.93) 41(45.56)
rs4551053 EBF1
Yes - - 160(100) 56(71.79) 104(48.83) 47(58.75) 63(52.07) 50(55.56)
No 112(100) 19(100) - 22(28.21) 109(51.17) 33(41.25) 58(47.93) 40(44.44)
rs4791040 PRKCA
Yes - - 110(68.75) 38(48.72) 72(33.80) 30(37.50) 42(34.71) 38(42.22)
No 112(100) 19(100) 50(31.25) 40(51.28) 141(66.20) 50(62.50) 79(65.29) 52(57.78)
rs5051 AGT
Yes - - 117(73.10) 41(52.56) 76(35.68) 31(38.75) 48(39.67) 38(42.22)
No 112(100) 19(100) 43(26.90) 37(47.44) 137(64.32) 49(61.25) 73(60.33) 52(57.78)
rs6083538 ZNF343
Yes - - 156(97.50) 56(71.79) 100(46.95) 46(57.50) 63(52.07) 47(52.22)
No 112(100) 19(100) 04(2.50) 22(28.21) 113(53.05) 34(42.50) 58(47.93) 43(47.78)
rs2070744 NOS3
Yes 112(100) 19(100) - 22(28.21) 109(51.17) 33(41.25) 58(47.93) 40(44.44)
No - - 160(100) 56(71.79) 104(48.83) 47(58.75) 63(52.07) 50(55.56)
rs7297610 YEATS4
Yes 112(100) 19(100) - 22(28.21) 109(51.17) 33(41.25) 58(47.93) 40(44.44)
No - - 160(100) 56(71.79) 104(48.83) 47(58.75) 63(52.07) 50(55.56)
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Xhosa Swati and Zulu Yoruba Luhya Mexican British Punjabi
rs11189015 C > G Intron 33.5 - 29.6 29.8 3.9 6.6 14.1
rs1458038 C > T Intergenic 20.3 - 94.4 97.5 73.4 73.6 77.1
rs16960228 C > T Intron 2.2 - 40.7 28.8 9.4 7.7 0.5
rs17010902 A > G Intergenic 59.5 - 0.5 3.5 26.0 8.8 16.1
rs2106809 A > G Intron 88.5 - 7.3 7.8 35.0 25.7 40.3
rs2107614 T > C Intron 53.5 - 38.9 53.0 64.8 73.1 69.3
rs2269879 C > T Intron 32.2 - 64.4 63.1 75.8 93.4 91.1
rs2277869 T > C Non-codingexon 20.5 - 13.0 17.7 18.0 14.3 19.3
rs2400707 A > G 5 primeUTR 37.26 - 56.9 43.3 82.8 60.4 70.8
rs2776546 C > A Regulatoryregion 48.7 - 41.2 40.4 26.6 17.0 13.0
rs292449 G > C 5 primeUTR 49.0 - 45.4 47.0 46.9 70.3 56.8
rs3184504 C > G Missense 100 - 100 100 22.7 50.0 7.3
rs4149601 G > A Spliceregion 51.5 - 37.5 50.0 11.7 31.3 18.8
rs4551053 G > A Regulatoryregion 13.6 - 11.1 11.6 16.4 33.0 43.2
rs4791040 T > C Intron 38.6 - 40.7 28.8 10.7 7.7 3.1
rs5051 C > T Intron 95.7 - 94.4 89.4 68.8 36.8 62.0
rs6083538 C > T Intron 15.0 - 7.9 9.1 46.9 47.8 37.5
rs2070744 C > T Intron - 14.7 12.5 14.1 27.3 46.3 25.5
rs7297610 Intergenic - 52.4 37.0 31.3 5.5 6.0 2.1
3.3. Association between SNPs and Blood Pressure Response to Hydrochlorothiazide
In the multivariate logistic regression (unadjusted) model analysis, the allele A of rs2400707
(OR = 7.34; 95%CI 3.05–17.67; p≤ 0.0001) was independently associated with uncontrolled hypertension,
although carriers of the genotype of rs2400707 AA (OR = 0.36; 95% CI 0.15–0.85; p = 0.020) were less
likely to have uncontrolled hypertension. No association was established in the remaining sixteen SNPs
detected among the Xhosa tribe. In the adjusted logistic regression model, the direction of association
for the A allele of rs2400707 shifted, and carriers of the A allele (OR = 0.14; 95%CI 0.03–0.665; p = 0.013)
were less likely to have uncontrolled hypertension. Furthermore, carriers of allele T of rs2107614 (AOR
= 6.69; 95%CI 1.42–31.55; p = 0.016) and C of rs2776546 (AOR = 3.78; 95%CI 1.04–13.74; p = 0.043) were
almost seven times and four times more likely to have uncontrolled hypertension, respectively. On the
other hand, carriers of rs4791040 allele C (AOR = 0.10; 95%CI 0.01–0.60; p = 0.012) were less likely to
have uncontrolled hypertension. After Bonferroni correction, all the alleles of rs2400707 (A), rs2107614
(T), rs2776546 (C) and rs4791040 remained significant with p-values < 0.0029 (Table 4).
Among Zulu and Swati participants, the multivariate logistic regression model analysis showed
that carriers of the genotype CC of rs2070744 (OR = 4.22; 95%CI 1.15–15.47; p = 0.030) were four
times more likely to be associated with uncontrolled hypertension, whilst rs2070744 TC (OR = 0.10;
95%CI 0.02–0.48; p = 0.004), rs7297610 CT (OR = 0.40; 95%CI 0.16–0.98; p = 0.045) and allele T
(OR = 0.60; 95%CI 0.36–0.98; p = 0.043) carriers were less likely to have uncontrolled hypertension.
After adjusting with each SNP, genotypes rs2070744 TC (AOR = 38.76 95%CI 5.54–270.76; p = 0.003)
and CC (AOR = 10.44; 95%CI 2.16–50.29; p = 0.00023) were significantly associated with uncontrolled
hypertension. In addition, allele T of rs7297610 (AOR = 1.86; 95%CI 1.09–3.14; p = 0.023) was
independently associated with uncontrolled hypertension. After Bonferroni correction, the genotypes
of rs2070744 and T allele of rs7297610 remained significantly associated with uncontrolled hypertension
(p < 0.0025) (Table 5).
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Table 4. Adjusted and unadjusted logistic regression models showing genotypes and alleles associated with blood pressure response to hydrochlorothiazide among
Xhosa patients (n = 160).
dbSNP Uncontrolled HPT (n; %) Controlled HPT (n; %) Unadjusted OddsRatios (95% CI) p-Value
Adjusted Odds






CC 11(84.62) 02(15.38) 1 1
GG 52(76.47) 16(23.53) 1.01(0.25–4.03) 0.982 0.82(0.30–2.22) 0.699 0.041
CG 62(83.78) 12(16.22) 1.14(0.49–2.62) 0.78(0.14–4.35) 0.786 0.046
Alleles
G 166(79.05) 44(20.95) 1 1
C 84(84.00) 16(16.00) 1.01(0.55–1.83) 0.969 1.65(0.40–6.70) 0.484 0.028
rs1458038
Genotypes
CC 89(81.65) 20(18.35) 1 1
TT 06(66.67) 03(33.33) 0.85(0.34–2.10) 0.727 2.32(0.32–16.87) 0.403 0.023
CT 39(86.67) 06(13.33) 0.47(0.10–2.25) 0.352 1.59(0.24–10.18) 0.622 0.036
Alleles
C 217(82.51) 46(17.49) 1 1
T 51(80.95) 12(19.05) 1.02(0.50–2.08) 0.939 0.85(0.19–3.74) 0.832 0.048
rs16960228
Genotypes
CC 123(81.46) 28(18.54) 1 1
TT - - - -
TC 04(57.14) 03(42.86) 2.19(0.51–9.32) 0.286 0.29(0.46–1.91) 0.201 0.011
Alleles
T 04(57.14) 03(42.86) 1 1
C 250(80.91) 59(19.09) 1.42(0.54–3.76) 0.470 4.11(0.74–22.58) 0.104 0.006
rs17010902
Genotypes
GG 44(86.27) 07(13.73) 1 1
AA 17(77.27) 05(22.73) 1.59(0.63–3.99) 0.45(0.98–2.12) 0.318 0.018
AG 61(77.22) 18(22.78) 1.33(0.44–4.01) 0.46(0.06–3.67) 0.471 0.027
Alleles
A 95(77.24) 28(22.76) 1 1
G 149(82.32) 32(17.68) 1.37(0.77–2.42) 0.275 0.34(0.57–2.10) 0.249 0.014
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Table 4. Cont.
dbSNP Uncontrolled HPT (n; %) Controlled HPT (n; %) Unadjusted OddsRatios (95% CI) p-Value
Adjusted Odds





GG 09(75.00) 03(25.00) 1 1
AA 109(81.95) 24(18.05) 0.75(0.13–4.25) 0.745 0.52(0.88–3.08) 0.472 0.027
AG 09(75.00) 03(25.00) 1.36(0.34–5.32) 0.657 0.40(0.75–2.16) 0.290 0.017
Alleles
G 27(75.00) 09(25.00) 1 1
A 227(81.65) 51(18.35) 1.48(0.65–3.34) 0.342 0.73(0.10–5.04) 0.752 0.044
rs2107614
Genotypes
CC 24(80.00) 06(20.00) 1 1
TT 33(80.49) 08(19.51) 1.06(0.38–3.00) 0.901 1.17(0.37–3.68) 0.786 0.046
TC 58(78.38) 16(21.62) 1.04(0.41–2.66) 0.923 1.04(0.23–4.57) 0.952 0.056
Alleles
C 106(79.10) 28(20.90) 1 1
T 124(79.49) 32(20.51) 1.01(0.57–1.77) 0.970 6.69(1.42–31.55) 0.016 0.0009
rs2269879
Genotypes
CC 60(83.33) 12(16.67) 1 1
TT 12(75.00) 04(25.00) 1.48(0.64–3.45) 0.357 0.63(0.11–3.44) 0.599 0.035
CT 53(77.94) 15(22.06) 0.92(0.26–3.23) 0.896 1.09(0.19–6.16) 0.918 0.054
Alleles
C 173(81.60) 39(18.40) 1 1
T 77(77.00) 23(23.00) 0.75(0.42–1.34) 0.342 1.49(0.33–6.65) 0.597 0.035
rs2277869
Genotypes
CC 03(75.00) 01(25.00) 1 1
TT 77(80.21) 19(19.79) 0.70(0.06–7.41) 0.769 0.46(0.02–7.88) 0.599 0.035
CT 45(80.36) 11(19.64) 0.97(0.42–2.22) 0.948 1.06(0.38–2.92) 0.899 0.052
Alleles
C 51(79.69) 13(20.31) 1 1
T 199(80.24) 49(19.76) 1.03(0.52–2.05) 0.921 0.32(0.06–1.64) 0.174 0.010
J. Pers. Med. 2020, 10, 267 10 of 17
Table 4. Cont.
dbSNP Uncontrolled HPT (n; %) Controlled HPT (n; %) Unadjusted OddsRatios (95% CI) p-Value
Adjusted Odds




GG 37(68.52) 17(31.48) 1 1
AA 22(88.00) 03(12.00) 0.36(0.15–0.85) 0.020 0.84(0.16–4.28) 0.842 0.049
AG 67(85.90) 11(14.10) 1.24(0.31–4.83) 0.757 0.27(0.05–1.30) 0.105 0.006
Alleles
G 141(75.81) 45(24.19) 1 1
A 111(86.72) 17(13.28) 7.34(3.05–17.67) <0.0001 0.14(0.03–0.66) 0.013 0.0007
rs2776546
Genotypes
AA 32(82.05) 07(17.95) 1 1
CC 29(82.86) 06(17.14) 1.28(0.48–3.38) 0.611 0.91(0.28–2.90) 0.878 0.051
CA 66(78.57) 18(21.43) 1.36(0.49–3.78) 0.551 1.12(0.28–4.40) 0.862
Alleles
A 130(80.25) 32(19.75) 1 1
C 124(80.52) 30(19.48) 1.01(0.58–1.77) 0.951 3.78(1.04–13.74) 0.043 0.0025
rs292449
Genotypes
GG 29(74.36) 10(25.64) 1 1
CC 35(83.33) 07(16.67) 0.68(0.27–1.73) 0.427 0.80(0.24–2.68) 0.723 0.043
GC 61(81.33) 14(18.67) 1.24(0.46–3.36) 0.665 0.59(0.16–2.41) 0.422
Alleles
G 119(77.78) 34(22.22) 1 1
C 131(82.39) 28(17.61) 1.33(0.76–2.33) 0.308 0.34(0.09–1.21) 0.097 0.005
rs3184504
Genotype
CC 128(80.50) 31(19.50) - - - -
Alleles
C 256(80.50) 62(19.50) - - - -
rs4149601
Genotypes
AA 34(85.00) 06(15.00) 1 1
GG 27(77.14) 08(22.86) 0.88(0.34–2.29) 0.806 0.59(0.17–2.07) 0.417 0.024
GA 67(79.76) 17(20.24) 1.43(0.51–3.98) 0.485 0.41(0.96–1.74) 0.228 0.013
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Table 4. Cont.
dbSNP Uncontrolled HPT (n; %) Controlled HPT (n; %) Unadjusted OddsRatios (95% CI) p-Value
Adjusted Odds




A 135(82.32) 29(17.68) 1 1
G 121(78.57) 33(21.43) 1.27(0.72–2.21) 0.400 1.98(0.52–7.52) 0.312 0.018
rs4551053
Genotypes
GG 95(78.51) 26(21.49) 1 1
AA 01(100) - - -
AG 33(86.84) 05(13.16) 0.55(0.19–1.57) 0.272 2.30(0.65–8.12) 0.714 0.042
Alleles
G 223(79.64) 57(20.36) 1 1
A 35(87.50) 05(12.50) 1.78(0.67–4.77) 0.245 0.17(0.01–2.00) 0.162 0.009
rs4791040
Genotypes
TT 44(86.27) 07(13.73) 1 1
CC 19(73.08) 07(26.92) 0.87(0.32–2.15) 0.713 0.97(0.21–4.37) 0.970 0.057
TC 26(78.79) 07(21.21 1.42(0.53–3.75) 0.478 0.50(0.08–2.84) 0.437 0.025
Alleles
T 114(84.44) 21(15.56) 1 1
C 64(75.29) 21(24.71) 1.78(0.90–3.50) 0.095 0.10(0.01–0.60) 0.018 0.0007
rs5051
Genotypes
CC - - - -
TT 88(82.24) 19(17.76) 1 1
CT 09(90.00) 01(10.00) 0.88(0.34–2.24) 0.796 1.24(0.39–3.95) 0.714 0.042
Alleles
C 9(90.00) 01(10.00) 1 1
T 185(82.59) 39(17.41) 0.52(0.06–4.28) 0.549 1.90(0.15–24.22) 0.618 0.036
rs6083538
Genotypes
CC 94(82.46) 20(17.54) 1 1
TT 02(50.00) 02(50.00) 1.44(0.59–3.51) 0.419 0.63(0.07–5.64) 0.686 0.040
CT 29(76.32) 09(23.68) 1.08(0.91–6.19) 0.926 0.99(0.13–7.56) 0.994 0.058
Alleles
C 217(81.58) 49(18.42) 1 1
T 33(71.74) 13(28.26) 0.57(0.28–1.16) 0.126 2.55(0.56–11.52) 0.221 0.013
HPT = Hypertension; dbSNP = single nucleotide polymorphism; CI = Confidence interval.
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Table 5. Adjusted and unadjusted logistic regression models showing genotypes and alleles associated with blood pressure response to hydrochlorothiazide among
Zulu and Swati patients (n = 131).
dbSNP Uncontrolled HPT (n; %) Controlled HPT (n; %) Unadjusted OddsRatios (95% CI) p-Value
Adjusted Odds






TT 53(55.79) 42(44.21) 1 1
CC 02(40.00) 03(60.00) 4.22(1.15–15.47) 0.030 10.44(2.16–50.29) 0.003 0.0015
TC 16(51.61) 15(48.39) 0.10(0.02–0.48) 0.004 38.76(5.54270.76) 0.00023 0.0001
Alleles
T 122(55.71) 99(44.29) 1 1
C 20(45.55) 21(57.45) 0.77(0.39–1.50) 0.449 1.68(0.82–3.42) 0.151 0.076
rs7297610
Genotypes
CC 27(54.00) 23(46.00) 1 1
TT 22(47.83) 24(52.17) 0.44(0.18–1.07) 0.07 2.28(8.55–6.11) 0.99 0.495
CT 21(61.76) 13(38.24) 0.40(0.16–0.98) 0.045 0.94(0.37–2.34) 0.898 0.449
Alleles
C 75(55.97) 59(44.03) 1 1
T 65(51.59) 61(48.41) 0.60(0.36–0.98) 0.043 1.86(1.09–3.14) 0.023 0.011
HPT = Hypertension; CI = Confidence interval, dbSNP = Single nucleotide polymorphism.
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4. Discussion
Thiazide diuretics are among the most prescribed anti-hypertensive drugs worldwide [24].
Furthermore, this class of drugs is recommended for the initial treatment of hypertension [4]. However,
pharmacogenetic markers of thiazide efficacy among African-specific populations are not well studied.
As such, there is a huge knowledge gap on the effect of SNPs and blood pressure response to thiazide
diuretics among populations of African origin. Therefore, this study described single nucleotide
polymorphisms (SNPs) in hydrochlorothiazide-associated genes and further assessed their correlation
with blood pressure control among South African adults living with hypertension.
Current research suggests that the genomes of indigenous African individuals carry the greatest
depth of genetic variation compared to other population groups from around the world [25].
Thus, studying African-specific populations could help researchers understand drug response
phenotypes in order to improve treatment outcomes for people living with hypertension. In the current
study, nineteen SNPs previously associated with hydrochlorothiazide efficacy in individuals with
hypertension were examined in 291 individuals belonging to the Zulu, Xhosa and Swati tribes (Nguni)
of South Africa. Seventeen SNPs were detected among the Xhosa tribe, and only two SNPs (rs2070744
and rs7297610) were detected among the Swati and Zulu people. The minor allele frequencies of
rs17010902, rs11189015, rs2277869 and rs2106809 were particularly higher among the Xhosa tribe
when compared to other populations (Yoruba, Luhya, Mexican, British and Punjabi), whilst rs6083538
showed a lower minor allele frequency when compared to non-African populations (Mexican, British
and Punjabi). The minor allele frequencies of the remainder of SNPs were comparable to the selected
African populations (Yoruba and Luhya) as well as those from other parts of the world. In addition,
the minor allele frequencies of the two SNPs detected among the Swati and Zulu people were also
compared with other population groups. Variant rs7297610 showed a higher minor allele frequency in
comparison to all the other population groups. Variant rs2070744 demonstrated a frequency similar
to that of Luhya people (Kenya), however, lower than the minor allele frequencies observed across
Mexican, British and Punjabi population groups. The genetic architecture of Nguni-speaking tribes has
been described as fairly homogeneous, however, the finding of this study suggests that some disparities
in blood pressure response to hydrochlorothiazide brought by SNPs that each tribe possesses may
exist. Although this panel of SNPs does not represent the entire human genome, it at least opens doors
for more genetic studies in order to gain a broader understanding of personalized treatment in patient
care, especially in individuals with hypertension. Findings from future studies with a larger sample
size drawn from the broader ethnically diverse population of South Africans might guide the selection
and dosing of thiazide diuretics as well as other hypertensive drugs.
The WNK1 gene encodes a protein that plays an important role in renal ion transport [13]. On the
other hand, the ADRB2 gene mediates a rise in intracellular cAMP concentration, which, through smooth
muscle relaxation, leads to vasodilation [4]. Blunted ADRB2 and WNK1 function have been implicated
in the pathogenesis of hypertension. In this study, the T allele of rs2107614 (WNK1) was significantly
associated with uncontrolled blood pressure among Xhosa participants, however, no association was
established with any of the genotypes. In contrast, Turner et al. (2005) showed that the genotypes CC
and CT of rs2107614 (WNK1) were associated with an increased reduction in whole-day ambulatory
blood pressure among individuals with non-complicated hypertension treated with HCTZ [8]. On the
other hand, this study showed that carriers of the A allele and the AA genotype of rs2400707
(ADRB2) were less likely to have uncontrolled blood pressure. These observations are in line with
previous findings, where the AA and AG genotypes of rs2400707 (ADRB2) were associated with an
increased reduction in whole-day ambulatory blood pressure in individuals with essential hypertension
undergoing HCTZ treatment [8]. These findings indicate that polymorphisms in genes regulating
renal sodium transport and smooth muscle relaxation may predict inter-individual variability in blood
pressure response to HCTZ. Furthermore, these genes as well as their SNPs may serve as therapeutic
markers for individualizing thiazide treatment for hypertensive patients of African ancestry.
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The variant rs2776545 occurs in the regulatory region of the CUB and Sushi multiple domains 1
(CSMD1) that encodes a product that functions as a complement control protein [26]. In this study,
allele C of rs2776546 was associated with uncontrolled blood pressure among patients belonging to
the Xhosa tribe. However, no association was established between HCTZ treatment response and
the genotypes of the SNPs. Conversely, a previous study showed that the A allele of rs2776546 was
associated with increased response to thiazide diuretics in people with hypertension as compared to
allele C. It was further demonstrated that carriers of the AA genotype of European ancestry treated with
HCTZ showed a greater reduction of diastolic blood pressure as compared to patients with the AC or
CC genotypes [14]. Moreover, the CSMD1 gene was associated with an increased risk of hypertension
among Korean patients [27,28]. Although the role of CSMD1 in the pathophysiology of hypertension is
not completely understood, the findings of this study bring attention to clinically relevant loci of blood
pressure response to thiazide diuretics among individuals of African ancestry and further highlight
the need for more studies with larger sample sizes that could validate the direction of association of
each allele and genotype.
The PRKCA gene is an important regulator of many physiological functions including secretion and
exocytosis, modulation of ion channel (Ca2+ ions) gene expression and cell growth and proliferation [29]
that harbors the SNP rs4791040. The current study showed that Xhosa carriers of the C allele of
rs4791040 were less likely to have uncontrolled blood pressure. Furthermore, a previous study
conducted among hypertensive patients of European origin showed that the allele T of rs4791040
was associated with decreased response to diuretics including hydrochlorothiazide as compared to
allele C. It was further demonstrated that carriers of TT genotype treated with HCTZ may have a
decreased reduction of diastolic blood pressure as compared to patients with the CC or CT genotypes [8].
Although no association was established between the genotypes of rs4791040 and blood pressure
response to hydrochlorothiazide in the present study, the current findings provide substantial evidence
that PRKCA polymorphisms may influence blood pressure response to hydrochlorothiazide owing to
their role in the modulation of ion channels.
Single nucleotide polymorphism rs2070744 is an intronic variant that sits on the NOS3 gene.
In addition, rs2070744 has been implicated in the variable response of thiazide diuretics. Carriers of
the CC genotype treated with anti-hypertensive drugs including HCTZ demonstrated an increased
risk of resistant hypertension as compared to TC and TT carriers [30]. It was further demonstrated
that carriers of the TC genotype may have a decreased, but not absent, risk for resistant hypertension.
Moreover, the authors described resistant hypertension as uncontrolled blood pressure when treated
with lifestyle measures and at least three anti-hypertensive drugs at maximum doses including a
diuretic. In the present study, uncontrolled hypertension was defined as blood pressure ≥140/90 mmHg
whilst on treatment. It should, however, be noted that lifestyle behaviors, doses of anti-hypertensive
drugs and the effect of individual drugs were not quantified in this study. The degree of association
between HCTZ treatment response and SNPs was solely measured without taking into consideration
other drugs administered. Furthermore, carriers of CC and TC genotypes (rs2070744) were more
likely to have uncontrolled hypertension. However, no clear association was established between
the alleles of rs2070744 and blood pressure response to HCTZ. Although the findings suggest a
significant association between the CC genotype and blood pressure response to hydrochlorothiazide,
the large difference between the numbers of alleles observed discounts this significance. Given the
large difference in numbers between the T allele and C allele, coupled with the uneven spread of
genotypes at this locus, it may be suggested that these findings are not significant but are instead a
product of skewed observations. Larger samples are required to definitively establish the observed
association in this study.
This study also investigated the effect of YEATS4 polymorphism (rs7297610) on blood pressure
response to hydrochlorothiazide. The T allele of rs7297610 was independently associated with
uncontrolled hypertension among Swati and Zulu patients. This study further demonstrated that
carriers of CT genotype were less likely to have uncontrolled blood pressure. The observations made in
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this study are in line with previous findings, where allele C was associated with an increased reduction
in blood pressure among individuals of mixed ancestry (African American and Afro-Caribbean) treated
with hydrochlorothiazide as compared to allele T [18]. Although other genetic and clinical factors
may also influence a patient’s response to hydrochlorothiazide, the study further demonstrated that
patients with the TT genotype treated with hydrochlorothiazide may have a decreased response as
compared to patients with the CC genotype [18]. Additionally, a haplotype made from three SNPs,
rs317689/rs315135/rs7297610 (ATC), was strongly associated with greater HCTZ response with the
ACT and ATT haplotypes correlating with a smaller blood pressure response [31]. Of note, the role
of YEATS4 in the development of hypertension remains elusive, however, previous findings and
observations made in this study suggest that polymorphism in this gene may predict blood pressure
response to thiazide diuretics among patients of African ancestry. It is also possible that the effect of
rs7297610 on HCTZ blood pressure response is a result of an interaction with other functional SNPs
not yet known. As such, more studies need to be conducted in order to explore the functional role of
YEATS4 and the mechanism in which it affects blood pressure in response to thiazide diuretics.
5. Conclusions
Using a candidate gene approach, we identified seventeen SNPs among the Xhosa tribe and
two SNPs among the Zulu and Swati tribes previously associated with hydrochlorothiazide efficacy
and hypertension. The minor alleles of rs2107614 and rs2776546 were independently associated
with uncontrolled hypertension among Xhosa participants. Furthermore, the T allele of rs7297610
was independently and significantly associated with uncontrolled hypertension among Swati and
Zulu participants. This study also provided preliminary information for the association of YEATS4
polymorphisms in blood pressure response to hydrochlorothiazide. However, replication of these
findings in a larger South African cohort is needed to confirm the associations observed in this study.
Further elucidation of the exact mechanism in which these SNPs affect blood pressure in response to
hydrochlorothiazide can ultimately aid in improving individualized anti-hypertensive therapy and the
identification of new drug targets.
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